All-oral, triple-acting HCV regimen cures more than 90% of cirrhotic cases

LONDON – More than 90% of patients with chronic hepatitis C and compensated cirrhosis treated with a triple-acting, all-oral, direct-acting antiviral (DAA) regimen achieved sustained virologic...